AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02161146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine
Description: One drop of olopatadine in the eye on Days 1 and 15.
Study NCT04082390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: 3 ml Levobupivacaine 0.5% (15mg) given intrathecally
Study NCT02613117 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Potassium Oxalate Gel
Description: Self applied
Study NCT00639054 — intervention group
Intervention type: PROCEDURE
Intervention: Blood samples
Description: 24 ml of cubital vein blood drawn in addition to diagnostic samples.
Study NCT00523354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
Study NCT04506554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMVAC + Nivolumab
Description: Nivolumab 240mg will be administered intravenously for 3 doses - on days 1, 15 and 29. AMVAC will be dosed intravenously every 2 weeks for 3 doses on days 1, 15 and 29 with Neulasta or equivalent. Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.
Study NCT03922724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOC
Description: e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2
Study NCT01096524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Physiotherapy
Description: The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.
Study NCT01096524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kneehab
Description: NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.~Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes.
Study NCT03629067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment T
Description: Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
Study NCT03629067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment R
Description: Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
Study NCT01708733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSY
Description: Chinese herbal formula
Study NCT02461563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg MK-1075
Description: Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
Study NCT02461563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg MK-1075
Description: Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levobupivacaine
Description: 3 ml Levobupivacaine 0.5% (15mg) given intrathecally
Study NCT03419234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT03419234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT03419234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
Study NCT03419234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiandrogen Therapy
Description: Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
Study NCT03419234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV
Study NCT03419234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03419234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03419234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Description: Undergo standard of care surgical castration with bilateral orchiectomy
Study NCT03419234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orchiectomy
Description: Undergo standard of care surgical castration with bilateral orchiectomy
Study NCT03419234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03419234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03419234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT03419234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT02613117 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Potassium Oxalate Liquid
Description: Professionally Applied
Study NCT02613117 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Stannous fluoride paste
Description: SnF2 Paste
Study NCT03831191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3375880
Description: Administered SC
Study NCT03831191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT04378465 — intervention group
Intervention type: OTHER
Intervention: Enhanced Recovery Program (ERP)
Description: An evidence-based perioperative care approach, involving a multidisciplinary team work including surgeons, anaesthesiologists, dieticians, and nurses, which aim to reduce the surgical stress and metabolic responses as well as organ dysfunction, thus leading to a faster recovery after surgery
Study NCT02182661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ba253BINEB
Study NCT02356419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin stimulating protein
Description: Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
Study NCT04314765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower third molar extraction
Description: the extraction is performed with one of the two type of flap based non randomization.
Study NCT01022957 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genetic diagnosis
Description: to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
Study NCT01471028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD treatment
Description: ELAD treatment consists of treatment with an extracorporeal liver assist system.
Study NCT01471028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care (Control)
Description: Control receives standard medical treatment.
Study NCT00688324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Acamprosate 333mg, ii tablets PO tid x 2 weeks
Study NCT00569244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: YAZ flex (SH T00186D)
Description: Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
Study NCT00569244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YAZ (SH T00186D)
Description: YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
Study NCT01175486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actos (Pioglitazone)
Description: Actos 30 mg for 6 months
Study NCT01175486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose 50 mg tid for 6 months
Study NCT00695955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil with or without add-on chlorthalidone
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
Study NCT00695955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil with or without add-on hydrochlorothiazide
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
Study NCT02106624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nitrogen supply
Description: Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
Study NCT02106624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nitrogen supply
Description: Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
Study NCT03645525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord-derived Mesenchymal stem cell
Description: The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10\^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube
Study NCT03645525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline
Study NCT03661424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2 BATs
Description: A test dose (1 million cells) of HER2 BATs (at one of the two dose levels: 5 million cells or 10 million cells per infusion) followed by 8 weekly infusions of Her2 BATs delivered into the ventricle of the brain. Infusions are delivered weekly over 8 weeks with brain MRIs prior to first infusion and following the eighth infusion. Blood will be drawn for immune evaluation before during and after study treatment.
Study NCT01311128 — intervention group
Intervention type: DEVICE
Intervention: T-line hemodynamic monitoring device (placement and use)
Description: The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This procedure will be repeated, for a second two-hour period, in the ICU postoperatively.
Study NCT03229772 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Discovery NM/CT 670 CZT Imaging Scan
Description: At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
Study NCT04243577 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tele-EaT Sensors
Description: Two iterations of a wearable surface EMG (sEMG) sensors patch we developed will be tested against commercially available wired devices. The first iteration of the wearable sensor patch is an ultrathin patch with a honeycomb-inspired design that included sEMG and strain sensors in order to capture muscle activity and thyroid movement signals from the submental area during swallows and swallow maneuvers/exercises. The second iteration is a more durable slightly thicker flexible, non-stretchable, and double-sided thin sEMG patch. Participants will perform standardized swallow tasks while wearing the device.
Study NCT04243577 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Sensors
Description: Conventional sensors will include snap-on wired electrodes as the control condition. The same set of standardized swallow tasks will be completed with the conventional and commercially available devices as well.
Study NCT02172131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL
Study NCT02172131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03057041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
Study NCT03057041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
Study NCT01961284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zygomatic implant placement
Study NCT01961284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional implants and augmentation of maxilla
Study NCT03626272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.
Study NCT02461563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg MK-1075
Description: Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: 3 ml Levobupivacaine 0.5% (15mg) given intrathecally
Study NCT01910610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FOLFIRI-cetuximab
Study NCT01910610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mFOLFOX6-bevacizumab
Study NCT01910610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPTIMOX-bevacizumab
Study NCT01910610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: irinotecan-based chemo + bevacizumab
Study NCT01910610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)
Study NCT01910610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XELOX + bevacizumab
Study NCT01093807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily for 10 weeks
Study NCT01093807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Description: 10 mg once daily for 10 weeks
Study NCT01093807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Description: 20 mg once daily for 10 weeks
Study NCT01093807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: 10 mg once daily for 10 weeks
Study NCT01093807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: 20 mg once daily for 10 weeks
Study NCT01093807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine + Enalapril
Description: 10/10 mg once daily for 10 weeks
Study NCT01093807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine + Enalapril
Description: 10/20 mg once daily for 10 weeks
Study NCT01093807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine + Enalapril
Description: 20/10 mg once daily for 10 weeks
Study NCT01093807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine + Enalapril
Description: 20/20 mg once daily for 10 weeks
Study NCT01566227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: 3 surveys with 10 questions each: one before, during and after treatment
Study NCT00971854 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Alteration of deep brain stimulator settings
Description: From 130Hz to 60Hz pallidal stimulation
Study NCT00971854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alteration of deep brain stimulator settings
Description: From 130Hz to 60Hz pallidal stimulation
Study NCT00162656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: half cyclophosphamide
Study NCT00162656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: without COPADM3
Study NCT00162656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mini CYVE, without 3 maintenance courses
Study NCT00162656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMB B
Study NCT00162656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMB C
Study NCT01287689 — intervention group
Intervention type: OTHER
Intervention: Immunoglobulin G (IgG)
Description: Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
Study NCT00553644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT00553644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00553644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01402492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine + Naltrexone
Description: Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
Study NCT01402492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Naltrexone
Description: Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
Study NCT01980992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wheat OIT
Description: Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
Study NCT01980992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wheat OIT
Description: Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
Study NCT00068497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT03453710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bankart Repair plus Remplissage
Description: Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space.
Study NCT03453710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latarjet coracoid transfer
Description: Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmetomidine intravenously
Description: Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmetomidine intravenously
Description: Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
Study NCT02966249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline added intrathecally
Description: Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty